The Medical Letter on Drugs and Therapeutics
Topical Oxybutynin (Gelnique) for Overactive Bladder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of a 10% topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride (Gelnique– Watson) for treatment of overactive bladder. Oxybutynin is also available for this indication as oral tablets, an oral syrup and a transdermal patch.1

TREATMENT OF OVERACTIVE BLADDER — Overactive bladder causes urgency, frequency, nocturia and incontinence, especially in the elderly. Antimuscarinic drugs are generally used to treat symptoms, but they cause dry mouth and constipation, and can cause confusion or cognitive loss in elderly patients.2

PHARMACOKINETICS — Transdermal administration of oxybutynin avoids first-pass metabolism, reducing the formation of N-desethyloxybutynin, an active metabolite.3 Following oral administration, serum concentrations of the active metabolite are ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Topical Oxybutynin (Gelnique) for Overactive Bladder
Article code: 1331b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian